Latest newsletter - exciting developments -->>

http://www.ldnresearchtrust.org/sites/default/files/May.pdf

LDN is going into a research trial for MS...at last.

Dr Jarred Younger said “ Our clinical trial will examine
100 individuals to determine how well LDN reduces MS
symptoms, improves functioning, and prevents disease
progression

Title of Project: Low-dose naltrexone for the treatment of
multiple sclerosis
Total Amount Needed for Successful Completion of
Study: £335,899
Project Timeframe: 3 years
Principal Investigator: Jarred Younger, PhD
Position Title:
Associate Professor: Department of Psychology
Associate Professor: Department of Anesthesiology and
Perioperative Medicine
Associate Professor: Division of Clinical Immunology and
Rheumatology
Director: Neuroinflammation, Pain and Fatigue Laboratory
Institute: University of Alabama at Birmingham

Abstract:
Low-dose naltrexone (LDN) is a promising treatment for
multiple sclerosis (MS), but clinical trials are needed before
the medication can be confidentially recommended for
mainstream medical practice. LDN is a novel antiinflammatory
in the brain and spinal cord, and may reduce
the abnormal immune activity that causes damage to
neurons. Previous trials have suggested that LDN can help
individuals with MS, but those studies had small sample
sizes or tested LDN for a short amount of time. Our clinical
trial will examine 100 individuals to determine how well LDN
reduces MS symptoms, improves functioning, and prevents
disease progression. LDN at a daily dosage of 4.5mg
appears to have very few side-effects, and has a long
history of safe use. The medication is also considerably
cheaper than mainstream MS medications, is commonly available,
and has few interactions with other medications.
The barrier to its widespread use is in properly conducted
trials demonstrating its efficacy and tolerability. This clinical
trial will provide the information that physicians and
policymakers need to determine if LDN should be
prescribed in the UK, USA, and elsewhere. We will study
multiple outcomes to determine how LDN improves pain."

cat

Hip-Huzzah - The newsletter this month has some excellent newsworthy items from doctors who are now prescribing LDN for several different diseases. Still a struggle to get the message out there, but are getting there - slowly. Yea !
_________________________
MollyC1i - Riding OutAS